Plain-English translation of NCT06952660 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is watching for eye-related side effects in people with cervical cancer that has returned or spread, who are being treated with . Researchers want to understand if and how this medication might affect your eyes, so they're asking participants to have regular eye exams throughout treatment and for a few months after.
While this medication has been approved to treat recurrent cervical cancer, researchers want to learn more about whether it can cause any eye problems. By carefully monitoring participants' eye health, they hope to catch any issues early and better understand how safe this treatment is.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (injection into a vein) once every 3 weeks for as long as it is working against your cancer. You would have eye exams before treatment starts, before each of your first 9 infusions, and then once a month for 3 months after you stop the medication. The study involves about 100 participants total and is being run by Pfizer.
AI-generated summary from trial data · Sep 20, 2026 · Not medical advice
United States